Drug Approval | November 21, 2025
Merck receives EU nod for first subcutaneous formulation, promising faster cancer treatment
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
Exemplifies commitment of Merck to energy efficiency and sustainable practices in high-performance computing by featuring advanced water-cooling systems and a hybrid cloud infrastructure
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
The move is expected to be crucial during health crises
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
The cleared system pairs a flexible nitinol implant with a deployable prong-locking mechanism, delivering rotational and length stability
Subscribe To Our Newsletter & Stay Updated
